AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33021649 — intervention group
Group type: COMPARATOR
Intervention: First email
Number of subjects: 56
Study 33021649 — intervention group
Group type: EXPERIMENTAL
Intervention: Third email
Number of subjects: 56
Study 33021649 — intervention group
Group type: EXPERIMENTAL
Intervention: New patients
Number of subjects: 56
Study 33021649 — intervention group
Group type: EXPERIMENTAL
Intervention: Established patients
Number of subjects: 56
Study 33446036 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app intervention group
Number of subjects: 100
Study 33446036 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 32734911 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 351
Study 32734911 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 351
Study 32734911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 351
Study 35763894 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (twice-a-week for 3 months)
Number of subjects: 85
Study 35763894 — intervention group
Group type: COMPARATOR
Intervention: Dual-task exercise program (simultaneous cognitive training with multicomponent exercises)
Number of subjects: 85
Study 35763894 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program
Number of subjects: 85
Study 35763894 — intervention group
Group type: COMPARATOR
Intervention: Dual-task exercise program
Number of subjects: 85
Study 32702363 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix (300 mg twice a day) with hormonal add-back therapy (1 mg estradiol/0.5 mg norethindrone acetate once a day)
Number of subjects: 2
Study 32702363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 32710671 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled participants (361 individuals)
Number of subjects: 3606
Study 32710671 — intervention group
Group type: COMPARATOR
Intervention: Decliners (3,147 individuals)
Number of subjects: 3606
Study 36027804 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical ayurvedic pharmaceutical form of herbal medicines
Number of subjects: 90
Study 36027804 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern extracts of Phyllanthus niruri and Sida cordifolia
Number of subjects: 90
Study 36027804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32562310 — intervention group
Group type: EXPERIMENTAL
Intervention: L-EVOO (250 mg total phenols kg-1 of oil)
Number of subjects: 12
Study 32562310 — intervention group
Group type: EXPERIMENTAL
Intervention: M-EVOO (500 mg total phenols kg-1 of oil)
Number of subjects: 12
Study 32562310 — intervention group
Group type: EXPERIMENTAL
Intervention: H-EVOO (750 mg total phenols kg-1 of oil)
Number of subjects: 12
Study 36352291 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-ounce bottles
Number of subjects: 40
Study 36352291 — intervention group
Group type: COMPARATOR
Intervention: Control group (own bottles)
Number of subjects: 40
Study 34181712 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 g/d S. cerevisiae fermentation product (SCFP)
Number of subjects: 18
Study 34181712 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (CON)
Number of subjects: 18
Study 35551088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention integrating PGHD with clinician and patient nudges (weekly text-based symptom surveys and passively recorded step counts)
Number of subjects: 125
Study 35551088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with additional text-based active choice intervention to encourage discussing symptoms
Number of subjects: 125
Study 35551088 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 125
Study 34397615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) prophylactic antibiotics
Number of subjects: 1906
Study 34397615 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) prophylactic antibiotics
Number of subjects: 1906
Study 32224762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive interventional therapy for brain AVMs
Number of subjects: 0
Study 32224762 — intervention group
Group type: COMPARATOR
Intervention: Observation with imaging for unruptured intracranial aneurysms
Number of subjects: 0
Study 32224762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment for unruptured intracranial aneurysms
Number of subjects: 0
Study 35804346 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive method (n=74)
Number of subjects: 439
Study 35804346 — intervention group
Group type: EXPERIMENTAL
Intervention: Group discussion by dentists (n=59)
Number of subjects: 439
Study 35804346 — intervention group
Group type: EXPERIMENTAL
Intervention: Face to face education by primary health care providers (n=53)
Number of subjects: 439
Study 35804346 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network applications (n=53)
Number of subjects: 439
Study 35804346 — intervention group
Group type: COMPARATOR
Intervention: Routine maternal and oral health care (Control group, n=200)
Number of subjects: 439
Study 33141921 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-based DAPT (600 mg on day 1, 150 mg on days 2-6)
Number of subjects: 44
Study 33141921 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-based DAPT
Number of subjects: 44
Study 33141921 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel single antiplatelet therapy (SAPT)
Number of subjects: 44
Study 34185278 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cheese with added calcium carbonate (CaCO3)
Number of subjects: 16
Study 34185278 — intervention group
Group type: COMPARATOR
Intervention: Standard cheese product
Number of subjects: 16
Study 33183928 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging (FI) with 0.25 mg/kg dosage
Number of subjects: 35
Study 33183928 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of residual fluorescence in the surgical bed
Number of subjects: 35
Study 34238894 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessive Thoughts (OT) and Compulsive Behavior (CB)
Number of subjects: 12532
Study 34238894 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessive Thoughts (OT)
Number of subjects: 12532
Study 34238894 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsive Behavior (CB)
Number of subjects: 12532
Study 34238894 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD with OT and CB
Number of subjects: 12532
Study 34238894 — intervention group
Group type: COMPARATOR
Intervention: Neither OT nor CB
Number of subjects: 12532
Study 32179197 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training plus neuromuscular exercise and education (ST + NEMEX-EDU)
Number of subjects: 90
Study 32179197 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular exercise and education alone (NEMEX-EDU)
Number of subjects: 90
Study 32179197 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 32198565 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrostomy drainage for > 24 hours prior to PCNL (group 1)
Number of subjects: 129
Study 32198565 — intervention group
Group type: COMPARATOR
Intervention: Concurrent percutaneous access during PCNL (group 2)
Number of subjects: 129
Study 32338624 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment and mobile app providing tailored smoking cessation support messages
Number of subjects: 240
Study 32338624 — intervention group
Group type: COMPARATOR
Intervention: Usual care (psychopharmacological treatment)
Number of subjects: 240
Study 32338624 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app engagement
Number of subjects: 240
Study 32338624 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to pharmacological therapy
Number of subjects: 240
Study 32338624 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical secondary objective measures
Number of subjects: 240
Study 35451359 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver meat balls (LMB) supplement, 3 times a week for 90 days
Number of subjects: 60
Study 35451359 — intervention group
Group type: COMPARATOR
Intervention: Control group with no supplement
Number of subjects: 60
Study 34144273 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 24 hours (FAS group)
Number of subjects: 22
Study 32776698 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Task‐oriented circuit training
Number of subjects: 31
Study 32776698 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment and home programmes)
Number of subjects: 31
Study 32776698 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 32242537 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention program (20 meetings, once a week)
Number of subjects: 276
Study 32242537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 276
Study 35411981 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM)
Number of subjects: 410
Study 35411981 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 410
Study 35411981 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher disease activity during follow‐up
Number of subjects: 410
Study 35411981 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug holidays of more than 11 weeks
Number of subjects: 410
Study 35411981 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher infliximab doses
Number of subjects: 410
Study 35411981 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum infliximab concentrations
Number of subjects: 410
Study 35411981 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline use of concomitant immunosuppressors
Number of subjects: 410
Study 35411981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of spondyloarthritis (SpA)
Number of subjects: 410
Study 35411981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of rheumatoid arthritis (RA)
Number of subjects: 410
Study 35411981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime smoking
Number of subjects: 410
Study 33677827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (oral 1,000 LRU/d) for 21 days
Number of subjects: 243
Study 33677827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 33216022 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with nigrostriatal degeneration (NSD)
Number of subjects: 36
Study 33216022 — intervention group
Group type: COMPARATOR
Intervention: Patients without nigrostriatal degeneration (NSD)
Number of subjects: 36
Study 33216022 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of patients with available [18F]FDG PET
Number of subjects: 36
Study 36424684 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose indomethacin/levonorgestrel-releasing intrauterine system
Number of subjects: 174
Study 36424684 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-dose indomethacin/levonorgestrel-releasing intrauterine system
Number of subjects: 174
Study 36424684 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose indomethacin/levonorgestrel-releasing intrauterine system
Number of subjects: 174
Study 36424684 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system without indomethacin
Number of subjects: 174
Study 36424684 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (including control)
Number of subjects: 174
Study 32914569 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal diet and physical activity intervention
Number of subjects: 514
Study 32914569 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 514
Study 32656664 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/Kg)
Number of subjects: 22
Study 32656664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34041884 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mm ceramic veneers with veneer adhesive system
Number of subjects: 20
Study 34041884 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mm ceramic veneers with veneer adhesive system
Number of subjects: 20
Study 34041884 — intervention group
Group type: COMPARATOR
Intervention: Dual-cured resin cements
Number of subjects: 20
Study 34041884 — intervention group
Group type: COMPARATOR
Intervention: Light-cured resin cements
Number of subjects: 20
Study 32711750 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal hyperglycemia (blood glucose concentrations ≥153 mg/dL)
Number of subjects: 57
Study 32711750 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without hyperglycemia)
Number of subjects: 57
Study 34990390 — intervention group
Group type: EXPERIMENTAL
Intervention: Peezy UCD
Number of subjects: 1174
Study 34990390 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiz Midstream UCD
Number of subjects: 1174
Study 34990390 — intervention group
Group type: COMPARATOR
Intervention: SVI (standardised verbal instructions)
Number of subjects: 1174
Study 33514359 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 64
Study 33514359 — intervention group
Group type: COMPARATOR
Intervention: Kyphoplasty (PKP)
Number of subjects: 64
Study 32517650 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 hours photoperiod with R/B/P/G light quality
Number of subjects: 0
Study 32517650 — intervention group
Group type: EXPERIMENTAL
Intervention: R/B/P/G light quality
Number of subjects: 0
Study 32517650 — intervention group
Group type: COMPARATOR
Intervention: White light (W)
Number of subjects: 0
Study 32517650 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoperiods (8h, 16h, 24h)
Number of subjects: 0
Study 33271352 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy (PRT36/12)
Number of subjects: 68
Study 33271352 — intervention group
Group type: COMPARATOR
Intervention: Concurrent Chemotherapy and Palliative Radiation Therapy (C-PRT40/20)
Number of subjects: 68
Study 35771234 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative peritoneal drain (D)
Number of subjects: 34
Study 35771234 — intervention group
Group type: COMPARATOR
Intervention: No post-operative peritoneal drain (ND)
Number of subjects: 34
Study 35771234 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised pus
Number of subjects: 34
Study 35771234 — intervention group
Group type: EXPERIMENTAL
Intervention: Localised pus
Number of subjects: 34
Study 34312689 — intervention group
Group type: EXPERIMENTAL
Intervention: Celect filter
Number of subjects: 136
Study 34312689 — intervention group
Group type: EXPERIMENTAL
Intervention: Denali filter
Number of subjects: 136
Study 35872847 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 503
Study 32086600 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoxia (SH; FiO20.13)
Number of subjects: 9
Study 32086600 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (MH; FiO20.17)
Number of subjects: 9
Study 32086600 — intervention group
Group type: COMPARATOR
Intervention: Sea level (SL; FiO20.21)
Number of subjects: 9
Study 32086600 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 9
Study 36029105 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 µg vaccine
Number of subjects: 70
Study 36029105 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 µg vaccine
Number of subjects: 70
Study 36029105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 36029105 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 70
Study 32101358 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate normal imputation
Number of subjects: 0
Study 32101358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully conditional specification methods
Number of subjects: 0
Study 35063897 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined perineal massage and warm compress (MassComp)
Number of subjects: 277
Study 35063897 — intervention group
Group type: COMPARATOR
Intervention: Perineal massage alone
Number of subjects: 277
Study 35105623 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone (200 mg orally) followed by misoprostol (800 µg vaginally)
Number of subjects: 294
Study 35105623 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (10 mg orally per day for 3 days) followed by misoprostol (800 µg vaginally on the third day)
Number of subjects: 294
Study 32965040 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) prevalence among women
Number of subjects: 11258
Study 32965040 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) prevalence among men
Number of subjects: 11258
Study 32965040 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of ID in women below 50 years
Number of subjects: 11258
Study 32965040 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with ID
Number of subjects: 11258
Study 32965040 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of ID in high-risk subgroups
Number of subjects: 11258
Study 32118551 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 279
Study 32118551 — intervention group
Group type: COMPARATOR
Intervention: IABP
Number of subjects: 279
Study 35428644 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional end‐to‐end anastomosis (FETE)
Number of subjects: 96
Study 35428644 — intervention group
Group type: COMPARATOR
Intervention: Side‐to‐side anastomosis (Overlap)
Number of subjects: 96
Study 33758306 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cornstarch diet (36%)
Number of subjects: 360
Study 33758306 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-cornstarch diet (18%)
Number of subjects: 360
Study 33758306 — intervention group
Group type: COMPARATOR
Intervention: Low-cornstarch diet (0%)
Number of subjects: 360
Study 32131365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (1000 IU/day)
Number of subjects: 31
Study 32131365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 33155824 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control (CLC) system
Number of subjects: 168
Study 33155824 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 168
Study 32707571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cd85‐xMgxTb15 alloys with varying x (5, 10, 15, 20)
Number of subjects: 0
Study 32707571 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmission electron microscopy analysis
Number of subjects: 0
Study 32707571 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical disorder due to randomized substitution of Cd with Mg
Number of subjects: 0
Study 32707571 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientational disorder of the Cd4 tetrahedra
Number of subjects: 0
Study 35038015 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-assisted training (group A)
Number of subjects: 92
Study 35038015 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (group B)
Number of subjects: 92
Study 33891615 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB/ACEI
Number of subjects: 210
Study 33891615 — intervention group
Group type: COMPARATOR
Intervention: non-ARB/ACEI
Number of subjects: 210
Study 33891615 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB
Number of subjects: 210
Study 33891615 — intervention group
Group type: COMPARATOR
Intervention: ACEI
Number of subjects: 210
Study 35615041 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS) for remote patient monitoring
Number of subjects: 0
Study 35615041 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth tools (apps and wearables)
Number of subjects: 0
Study 36372347 — intervention group
Group type: EXPERIMENTAL
Intervention: MNV type 3
Number of subjects: 1097
Study 36372347 — intervention group
Group type: EXPERIMENTAL
Intervention: MNV type 1
Number of subjects: 1097
Study 36372347 — intervention group
Group type: EXPERIMENTAL
Intervention: MNV type 2
Number of subjects: 1097
Study 36372347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed type 1 and 2
Number of subjects: 1097
Study 36372347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eye MA
Number of subjects: 1097
Study 36372347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 1097
Study 33054811 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based ReHub-assisted telerehabilitation
Number of subjects: 56
Study 33054811 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation during the 2-week stay in the rehabilitation clinic followed by 3 weeks of unsupervised home-based rehabilitation
Number of subjects: 56
Study 35179431 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise program
Number of subjects: 125
Study 35179431 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 33154085 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II-stimulating antihypertensives
Number of subjects: 1909
Study 33154085 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II-inhibiting antihypertensives
Number of subjects: 1909
Study 33154085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both antihypertensive types
Number of subjects: 1909
Study 32807086 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (rosuvastatin)
Number of subjects: 227
Study 32807086 — intervention group
Group type: COMPARATOR
Intervention: Non-statin therapy (placebo)
Number of subjects: 227
Study 35410935 — intervention group
Group type: EXPERIMENTAL
Intervention: Two video consultations conducted by a mental health specialist (MHS)
Number of subjects: 50
Study 35410935 — intervention group
Group type: EXPERIMENTAL
Intervention: Five video consultations conducted by a mental health specialist (MHS)
Number of subjects: 50
Study 35410935 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual provided by their GP
Number of subjects: 50
Study 33931037 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacarie-Duo
Number of subjects: 162
Study 33931037 — intervention group
Group type: COMPARATOR
Intervention: ART
Number of subjects: 162